A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University of Southern California
Memorial Sloan Kettering Cancer Center
Deciphera Pharmaceuticals, LLC
Assistance Publique - Hôpitaux de Paris
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
BBB-Therapeutics B.V.
National Cancer Institute (NCI)
GE Healthcare
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Thallion Pharmaceuticals